NASDAQ · APGE
Healthcare · Biotechnology
$135.07
Up+$0.00 (+0.00%)
Updated Sep 10, 2026, 10:03 PM
SID Score
6.6/10
Composite research score
Smart Money
58/100
Neutral
Price performance
1M range · 16 trading sessions · Daily adjusted prices
APGE closed at $135.07 after 16 trading sessions, up 0.39% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 2, 2026 | $135.08 | $135.09 | $135.06 | $135.07 | 5.14M |
| Sep 1, 2026 | $135.03 | $135.09 | $135.01 | $135.08 | 1.09M |
| Aug 31, 2026 | $135.00 | $135.08 | $134.99 | $135.08 | 1.81M |
| Aug 28, 2026 | $134.95 | $134.975 | $134.93 | $134.97 | 733.86K |
| Aug 27, 2026 | $134.93 | $134.98 | $134.91 | $134.96 | 1.14M |
| Aug 26, 2026 | $134.83 | $134.99 | $134.81 | $134.95 | 1.61M |
| Aug 25, 2026 | $134.85 | $134.86 | $134.81 | $134.85 | 655.84K |
| Aug 24, 2026 | $134.75 | $134.83 | $134.71 | $134.79 | 1.15M |
| Aug 21, 2026 | $134.79 | $134.82 | $134.70 | $134.75 | 948.28K |
| Aug 20, 2026 | $134.72 | $134.80 | $134.68 | $134.75 | 1.16M |
| Aug 19, 2026 | $134.83 | $134.88 | $134.70 | $134.71 | 1.42M |
| Aug 18, 2026 | $134.55 | $134.60 | $134.54 | $134.57 | 992.19K |
| Aug 17, 2026 | $134.53 | $134.60 | $134.51 | $134.59 | 1.95M |
| Aug 14, 2026 | $134.45 | $134.585 | $134.45 | $134.55 | 1.48M |
| Aug 13, 2026 | $134.59 | $134.595 | $134.40 | $134.45 | 1.26M |
| Aug 12, 2026 | $134.66 | $134.70 | $134.55 | $134.55 | 802.27K |
The latest Smart Investors Daily articles mentioning APGE.
APGE research
Company profile and research snapshot.
Apogee Therapeutics Inc is a biotechnology company seeking to develop differentiated biologics for the treatment of atopic dermatitis (AD), chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology (I&I) indications with high unmet need. Its antibody programs are designed to overcome the limitations of existing therapies by targeting well-established mechanisms of action and incorporating antibody engineering to optimize half-life and other properties.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Aug 13, 2026 | Truist Securities | Hold | — |
| Aug 12, 2026 | BTIG | Neutral | — |
| Jun 24, 2026 | Stifel | Hold | — |
| Jun 24, 2026 | TD Cowen | Hold | — |
| Jun 24, 2026 | Mizuho | Neutral | — |
No generated briefing is available yet.
Yahoo · Sep 3, 2026
AbbVie (NYSE: ABBV) today announced that it has completed its acquisition of Apogee Therapeutics, Inc. (NASDAQ: APGE). With completion of the acquisition, Apogee is now part of AbbVie. Under the terms of the agreement, Apogee shareholders received $135.11 per share in cash, for a total equity value of approximately $10.9 billion.
Yahoo · Sep 2, 2026
Kymera Therapeutics' (KYMR) KT-621 could validate its "oral Dupixent" potential, but with a roughly
Yahoo · Aug 30, 2026
What AbbVie’s Skyrizi EMA filing means for ABBV stock AbbVie (ABBV) has moved to expand Skyrizi’s role in Crohn's disease treatment by submitting an application to the European Medicines Agency for a subcutaneous induction regimen in adults with moderately to severely active disease. The filing, backed by Phase 3 AFFIRM data, comes as AbbVie stock reflects a mixed recent pattern, with the share price down over the past week but higher over the past month, past 3 months and past year. At a...
Yahoo · Aug 29, 2026
Eli Lilly's metabolic therapies drove 45% revenue growth, but its valuation premium demands scrutiny against AbbVie's defensive dividend appeal.
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning APGE.
